These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
277 related articles for article (PubMed ID: 7660140)
1. Comparative studies on the anticoagulant and protease generation inhibitory actions of newly developed site-directed thrombin inhibitory drugs. Efegatran, argatroban, hirulog, and hirudin. Callas DD; Hoppensteadt D; Fareed J Semin Thromb Hemost; 1995; 21(2):177-83. PubMed ID: 7660140 [TBL] [Abstract][Full Text] [Related]
2. BCH-2763, a novel potent parenteral thrombin inhibitor, is an effective antithrombotic agent in rodent models of arterial and venous thrombosis--comparisons with heparin, r-hirudin, hirulog, inogatran and argatroban. Finkle CD; St Pierre A; Leblond L; Deschenes I; DiMaio J; Winocour PD Thromb Haemost; 1998 Feb; 79(2):431-8. PubMed ID: 9493603 [TBL] [Abstract][Full Text] [Related]
3. A family of arginal thrombin inhibitors related to efegatran. Smith GF; Shuman RT; Craft TJ; Gifford DS; Kurz KD; Jones ND; Chirgadze N; Hermann RB; Coffman WJ; Sandusky GE; Roberts E; Jackson CV Semin Thromb Hemost; 1996; 22(2):173-83. PubMed ID: 8807715 [TBL] [Abstract][Full Text] [Related]
4. Effective use of BCH-2763, a new potent injectable direct thrombin inhibitor, in combination with tissue plasminogen activator (tPA) in a rat arterial thrombolysis model. Deschênes I; Finkle CD; Winocour PD Thromb Haemost; 1998 Jul; 80(1):186-91. PubMed ID: 9684808 [TBL] [Abstract][Full Text] [Related]
5. Differences in the clinically effective molar concentrations of four direct thrombin inhibitors explain their variable prothrombin time prolongation. Warkentin TE; Greinacher A; Craven S; Dewar L; Sheppard JA; Ofosu FA Thromb Haemost; 2005 Nov; 94(5):958-64. PubMed ID: 16363236 [TBL] [Abstract][Full Text] [Related]
6. Laboratory assays for the evaluation of recombinant hirudin. Walenga JM; Hoppensteadt D; Koza M; Wallock M; Pifarre R; Fareed J Haemostasis; 1991; 21 Suppl 1():49-63. PubMed ID: 1894197 [TBL] [Abstract][Full Text] [Related]
7. Anticoagulant activity of Hirulog, a direct thrombin inhibitor, in humans. Fox I; Dawson A; Loynds P; Eisner J; Findlen K; Levin E; Hanson D; Mant T; Wagner J; Maraganore J Thromb Haemost; 1993 Feb; 69(2):157-63. PubMed ID: 8456428 [TBL] [Abstract][Full Text] [Related]
8. The effect of antithrombin III-independent thrombin inhibitors and heparin on fibrin accretion onto fibrin-coated polyethylene. Rubens FD; Weitz JI; Brash JL; Kinlough-Rathbone RL Thromb Haemost; 1993 Feb; 69(2):130-4. PubMed ID: 8456425 [TBL] [Abstract][Full Text] [Related]
9. Inhibition of thrombin generation in plasma by inhibitors of factor Xa. Prasa D; Svendsen L; Stürzebecher J Thromb Haemost; 1997 Oct; 78(4):1215-20. PubMed ID: 9364987 [TBL] [Abstract][Full Text] [Related]
10. Effects of the synthetic thrombin inhibitor argatroban on fibrin- or clot-incorporated thrombin: comparison with heparin and recombinant Hirudin. Berry CN; Girardot C; Lecoffre C; Lunven C Thromb Haemost; 1994 Sep; 72(3):381-6. PubMed ID: 7855788 [TBL] [Abstract][Full Text] [Related]
11. The anticoagulant mechanism of action of recombinant hirudin (CGP 39393) in plasma. Lindhout T; Blezer R; Hemker HC Thromb Haemost; 1990 Nov; 64(3):464-8. PubMed ID: 2096492 [TBL] [Abstract][Full Text] [Related]
12. Direct thrombin inhibitors and factor xa inhibitors can influence the diluted prothrombin time used as the initial screen for lupus anticoagulant. Olah Z; Szarvas M; Bereczky Z; Kerenyi A; Kappelmayer J; Boda Z Arch Pathol Lab Med; 2013 Jul; 137(7):967-73. PubMed ID: 23808469 [TBL] [Abstract][Full Text] [Related]
13. Direct thrombin inhibitors in cardiovascular disease. Catella-Lawson F Coron Artery Dis; 1997 Feb; 8(2):105-11. PubMed ID: 9211051 [TBL] [Abstract][Full Text] [Related]
14. Distinct features of bivalent direct thrombin inhibitors, hirudin and bivalirudin, revealed by clot waveform analysis and enzyme kinetics in coagulation assays. Wakui M; Fujimori Y; Nakamura S; Kondo Y; Kuroda Y; Oka S; Nakagawa T; Katagiri H; Murata M J Clin Pathol; 2019 Dec; 72(12):817-824. PubMed ID: 31366633 [TBL] [Abstract][Full Text] [Related]
15. The ability of thrombin inhibitors to reduce the thrombin activity generated in plasma on extrinsic and intrinsic activation. Prasa D; Svendsen L; Stürzebecher J Thromb Haemost; 1997 Mar; 77(3):498-503. PubMed ID: 9066001 [TBL] [Abstract][Full Text] [Related]
16. A quantitative thrombin time for determining levels of hirudin and Hirulog. Reid TJ; Alving BM Thromb Haemost; 1993 Oct; 70(4):608-16. PubMed ID: 8115987 [TBL] [Abstract][Full Text] [Related]
17. Anticoagulant effects of hirulog, a novel thrombin inhibitor, in patients with coronary artery disease. Cannon CP; Maraganore JM; Loscalzo J; McAllister A; Eddings K; George D; Selwyn AP; Adelman B; Fox I; Braunwald E Am J Cardiol; 1993 Apr; 71(10):778-82. PubMed ID: 8456753 [TBL] [Abstract][Full Text] [Related]
18. Direct thrombin inhibitors for treatment of arterial thrombosis: potential differences between bivalirudin and hirudin. Bates SM; Weitz JI Am J Cardiol; 1998 Oct; 82(8B):12P-18P. PubMed ID: 9809887 [TBL] [Abstract][Full Text] [Related]
19. Inhibition by Argatroban, a specific thrombin inhibitor, of platelet activation by fibrin clot-associated thrombin. Lunven C; Gauffeny C; Lecoffre C; O'Brien DP; Roome NO; Berry CN Thromb Haemost; 1996 Jan; 75(1):154-60. PubMed ID: 8713795 [TBL] [Abstract][Full Text] [Related]
20. The antithrombotic effect of a novel hirudin derivative after reconstruction of carotid artery in rabbits. Lu WF; Mo W; Liu Z; Fu WG; Guo DQ; Wang YQ; Song HY Thromb Res; 2010 Oct; 126(4):e339-43. PubMed ID: 20483158 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]